Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma

Min Yao, Charles Woods, Pierre Lavertu, Pingfu Fu, Michael Gibson, Rod Rezaee, Chad Zender, Jay Wasman, Neelesh Sharma, Mitchell Machtay, Panayiotis Savvides

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background The purpose of this study was to establish the efficacy and toxicities of concurrent erlotinib and docetaxel with intensity-modulated radiotherapy (IMRT) for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Patients received daily erlotinib for 2 weeks, followed by daily IMRT with concurrent weekly docetaxel and daily erlotinib, followed by daily erlotinib for up to 2 years. The primary objective was disease-free survival (DFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities. Forty-three patients were recruited for this study. Results With a median follow-up of 48.7 months, the 3-year DFS, OS, locoregional failure-free survival, and distant metastasis-free survival was 69.5%, 81%, 82.4%, and 83.7%, respectively. The most common grade III/IV local toxicities were dysphagia, dermatitis, and mucositis. Patients with p16-positive tumors had significantly better outcomes. Conclusion The regimen is tolerable and effective. It is worthy of further investigation in selected patients and may be useful in patients who cannot tolerate cisplatin.

Original languageEnglish (US)
Pages (from-to)E1770-E1776
JournalHead and Neck
Volume38
DOIs
StatePublished - Apr 1 2016

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this